GlassScriptPhysician profile
Erin Unen
NPI 1295781466
$4,755.86
in general payments reported to CMS, 2019-2025
27 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $582 · 2023: $961 · 2024: $1,079 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,896 · Education: $22.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,895.93 |
| Education | $22.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.94 | 2021-2025 | |
| Janssen Biotech, INC. | $857.79 | 2021-2025 | Stelara, Tremfya, Simponi |
| Madrigal Pharmaceuticals | $389.39 | 2024-2025 | Rezdiffra |
| Ardelyx, INC. | $364.94 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $297.14 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.51 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $246.18 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.65 | 2021-2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $95.46 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $92.37 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $88.19 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $84.09 | 2023-2025 | |
| Braintree Laboratories, INC. | $75.14 | 2021-2025 | Suflave, Sutab |
| Fresenius Kabi USA, LLC | $68.39 | 2023-2024 | Idacio |
| Vivus LLC | $68.09 | 2025 | Qsymia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $66.02 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $62.19 | 2021-2023 | Linzess |
| Organon LLC | $50.48 | 2024-2025 | Hadlima, Renflexis |
| Celgene Corporation | $44.72 | 2021-2024 | Zeposia |
| Biocon Biologics INC | $23.37 | 2025 | Yesintek |
| Novo Nordisk INC | $23.01 | 2023 | Wegovy |
| Medtronic, INC. | $18.83 | 2022 | |
| Aimmune Therapeutics, INC. | $17.92 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.47 | 2025 | Iqirvo |
| Amgen INC. | $14.96 | 2025 | Uplizna |
| Evoke Pharma, INC. | $14.62 | 2025 | |
| Nestle Healthcare Nutrition INC. | $14.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Unen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.